Cargando…

The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism

Fibroblast growth factor-23 (FGF23), a phosphate(Phos)-regulating hormone, is abnormally elevated in hypophosphataemic syndromes and an elevated FGF23 is a predictor of mortality in kidney disease. Recent findings suggest iron deficiency as a potential mediator of FGF23 expression and murine studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Braithwaite, V.S., Prentice, A., Darboe, M.K., Prentice, A.M., Moore, S.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720219/
https://www.ncbi.nlm.nih.gov/pubmed/26453792
http://dx.doi.org/10.1016/j.bone.2015.10.003
_version_ 1782411061436088320
author Braithwaite, V.S.
Prentice, A.
Darboe, M.K.
Prentice, A.M.
Moore, S.E.
author_facet Braithwaite, V.S.
Prentice, A.
Darboe, M.K.
Prentice, A.M.
Moore, S.E.
author_sort Braithwaite, V.S.
collection PubMed
description Fibroblast growth factor-23 (FGF23), a phosphate(Phos)-regulating hormone, is abnormally elevated in hypophosphataemic syndromes and an elevated FGF23 is a predictor of mortality in kidney disease. Recent findings suggest iron deficiency as a potential mediator of FGF23 expression and murine studies have shown in utero effects of maternal iron deficiency on offspring FGF23 and phosphate metabolism. Our aim was to investigate the impact of maternal iron status on infant FGF23 and mineral metabolites over the first 2 years of life. Infants born to mothers with normal (NIn = 25,) and low (LIn = 25) iron status during pregnancy, from a mother-infant trial (ISRCTN49285450) in rural Gambia, West Africa, had blood and plasma samples analysed at 12, 24, 52, 78 and 104 weeks (wk) of age. Circulating intact-FGF23 (I-FGF23), Phos, total alkaline phosphatase (TALP) and haemoglobin (Hb) decreased and estimated glomerular filtration rate increased over time [all P ≤ 0.0001)]. C-terminal-FGF23 (C-FGF23) and TALP were significantly higher in LI compared with NI, from 52 wk for C-FGF23 [Beta coefficient (SE) 18.1 (0.04) %, P = 0.04] and from 24 wk for TALP [44.7 (29.6) U/L, P = 0.04]. Infant Hb was the strongest negative predictor of C-FGF23 concentration [− 21% (4%) RU/mL, P ≤ 0.0001], Phos was the strongest positive predictor of I-FGF23 [32.0(3.9) pg/mL, P ≤ 0.0001] and I-FGF23 did not predict C-FGF23 over time [− 0.5% (0.5%), P = 0.3]. In conclusion, this study suggests that poor maternal iron status is associated with a higher infant C-FGF23 and TALP but similar I-FGF23 concentrations in infants and young children. These findings further highlight the likely public health importance of preventing iron deficiency during pregnancy. Whether or not children who are born to iron deficient mothers have persistently high concentrations of these metabolites and are more likely to be at risk of impaired bone development and pre-disposed to rickets requires further research.
format Online
Article
Text
id pubmed-4720219
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-47202192016-02-16 The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism Braithwaite, V.S. Prentice, A. Darboe, M.K. Prentice, A.M. Moore, S.E. Bone Original Full Length Article Fibroblast growth factor-23 (FGF23), a phosphate(Phos)-regulating hormone, is abnormally elevated in hypophosphataemic syndromes and an elevated FGF23 is a predictor of mortality in kidney disease. Recent findings suggest iron deficiency as a potential mediator of FGF23 expression and murine studies have shown in utero effects of maternal iron deficiency on offspring FGF23 and phosphate metabolism. Our aim was to investigate the impact of maternal iron status on infant FGF23 and mineral metabolites over the first 2 years of life. Infants born to mothers with normal (NIn = 25,) and low (LIn = 25) iron status during pregnancy, from a mother-infant trial (ISRCTN49285450) in rural Gambia, West Africa, had blood and plasma samples analysed at 12, 24, 52, 78 and 104 weeks (wk) of age. Circulating intact-FGF23 (I-FGF23), Phos, total alkaline phosphatase (TALP) and haemoglobin (Hb) decreased and estimated glomerular filtration rate increased over time [all P ≤ 0.0001)]. C-terminal-FGF23 (C-FGF23) and TALP were significantly higher in LI compared with NI, from 52 wk for C-FGF23 [Beta coefficient (SE) 18.1 (0.04) %, P = 0.04] and from 24 wk for TALP [44.7 (29.6) U/L, P = 0.04]. Infant Hb was the strongest negative predictor of C-FGF23 concentration [− 21% (4%) RU/mL, P ≤ 0.0001], Phos was the strongest positive predictor of I-FGF23 [32.0(3.9) pg/mL, P ≤ 0.0001] and I-FGF23 did not predict C-FGF23 over time [− 0.5% (0.5%), P = 0.3]. In conclusion, this study suggests that poor maternal iron status is associated with a higher infant C-FGF23 and TALP but similar I-FGF23 concentrations in infants and young children. These findings further highlight the likely public health importance of preventing iron deficiency during pregnancy. Whether or not children who are born to iron deficient mothers have persistently high concentrations of these metabolites and are more likely to be at risk of impaired bone development and pre-disposed to rickets requires further research. Elsevier Science 2016-02 /pmc/articles/PMC4720219/ /pubmed/26453792 http://dx.doi.org/10.1016/j.bone.2015.10.003 Text en © 2015 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Full Length Article
Braithwaite, V.S.
Prentice, A.
Darboe, M.K.
Prentice, A.M.
Moore, S.E.
The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism
title The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism
title_full The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism
title_fullStr The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism
title_full_unstemmed The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism
title_short The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism
title_sort effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism
topic Original Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720219/
https://www.ncbi.nlm.nih.gov/pubmed/26453792
http://dx.doi.org/10.1016/j.bone.2015.10.003
work_keys_str_mv AT braithwaitevs theeffectsofmaternalirondeficiencyoninfantfibroblastgrowthfactor23andmineralmetabolism
AT prenticea theeffectsofmaternalirondeficiencyoninfantfibroblastgrowthfactor23andmineralmetabolism
AT darboemk theeffectsofmaternalirondeficiencyoninfantfibroblastgrowthfactor23andmineralmetabolism
AT prenticeam theeffectsofmaternalirondeficiencyoninfantfibroblastgrowthfactor23andmineralmetabolism
AT moorese theeffectsofmaternalirondeficiencyoninfantfibroblastgrowthfactor23andmineralmetabolism
AT braithwaitevs effectsofmaternalirondeficiencyoninfantfibroblastgrowthfactor23andmineralmetabolism
AT prenticea effectsofmaternalirondeficiencyoninfantfibroblastgrowthfactor23andmineralmetabolism
AT darboemk effectsofmaternalirondeficiencyoninfantfibroblastgrowthfactor23andmineralmetabolism
AT prenticeam effectsofmaternalirondeficiencyoninfantfibroblastgrowthfactor23andmineralmetabolism
AT moorese effectsofmaternalirondeficiencyoninfantfibroblastgrowthfactor23andmineralmetabolism